Bristol-Myers Squibb Co. (NYSE: BMY) entered an exclusive
strategic collaboration with uniQure N.V. (Nasdaq: QURE) to develop gene
therapies for cardiovascular diseases. Shares of Bristol-Myers slipped
23 cents to close at $63.00 while uniQure stock leaped $10.75 to close
at $33.61.
Bristol-Myers enters agreement with uniQure
April 06, 2015 at 17:45 PM EDT